Experienced in Denys-Drash Syndrome (DDS)
Experienced in Denys-Drash Syndrome (DDS)
Stony Brook Children's Service, University Faculty Practice Corporatio
2701 Sunrise Hwy, 
Islip Terrace, NY 

Overview

Laura Hogan is a Pediatric Hematologist Oncology provider in Islip Terrace, New York. Dr. Hogan is rated as an Experienced provider by MediFind in the treatment of Denys-Drash Syndrome (DDS). Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Rhabdomyosarcoma, Infantile Neutropenia, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 19 peer reviewed articles and participating in 26 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 6 clinical trials in the study of Denys-Drash Syndrome (DDS).

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in NY
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

STONY BROOK CHILDREN'S SERVICE, UNIVERSITY FACULTY PRACTICE CORPORATIO
2701 Sunrise Hwy, Islip Terrace, NY 11752

Additional Areas of Focus

Dr. Hogan has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


26 Clinical Trials

Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Renal Tumors Classification, Biology, and Banking Study
Key Adverse Events After Childhood Cancer
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
View 25 Less Clinical Trials
Similar Doctors
Advanced in Denys-Drash Syndrome (DDS)
Pediatric Hematology Oncology
Advanced in Denys-Drash Syndrome (DDS)
Pediatric Hematology Oncology
20 York St, Ynhh (children's) West Pavilion - 2nd Floor, 
New Haven, CT 
 (41.1 miles away)
Languages Spoken:
English

Nina Kadan is a Pediatric Hematologist Oncology provider in New Haven, Connecticut. Dr. Kadan is rated as a Distinguished provider by MediFind in the treatment of Denys-Drash Syndrome (DDS). Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Embryonal Tumor with Multilayered Rosettes, Hepatoblastoma, and Bone Marrow Aspiration.

Advanced in Denys-Drash Syndrome (DDS)
Pediatric Hematology Oncology
Advanced in Denys-Drash Syndrome (DDS)
Pediatric Hematology Oncology
5645 Main St, 
Flushing, NY 
 (32.8 miles away)
Languages Spoken:
English

Alexander Aledo is a Pediatric Hematologist Oncology provider in Flushing, New York. Dr. Aledo is rated as an Advanced provider by MediFind in the treatment of Denys-Drash Syndrome (DDS). His top areas of expertise are Langerhans Cell Histiocytosis, Histiocytosis, Reticulohistiocytoma, Hepatoblastoma, and Bone Marrow Aspiration.

Julie I. Krystal
Advanced in Denys-Drash Syndrome (DDS)
Pediatric Hematology Oncology | Pediatrics | Oncology
Advanced in Denys-Drash Syndrome (DDS)
Pediatric Hematology Oncology | Pediatrics | Oncology

Northwell Health Pediatric Hematology/Oncology & Stem Cell Transplant

269-01 76th Avenue, Suite 255, 
New Hyde Park, NY 
 (26.7 miles away)
Experience:
17+ years
Languages Spoken:
English

Julie Krystal is a Pediatrics specialist and an Oncologist in New Hyde Park, New York. Dr. Krystal has been practicing medicine for over 17 years and is rated as an Advanced provider by MediFind in the treatment of Denys-Drash Syndrome (DDS). Her top areas of expertise are Neuroblastoma, Medulloblastoma, Acute Lymphoblastic Leukemia (ALL), Rhabdomyosarcoma, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hogan's expertise for a condition
ConditionClose
      View All 19 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile